menu
    • menu
    [{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Salubris Biotherapeutics

    Menu

    Salubris Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Salubris Biotherapeutics Announces Positive Interim Data for JK07 in Heart Failure

                            Details : JK07 is a recombinant fusion protein consisting of a fully human IgG1 monoclonal antibody, which is being evaluated for the treatment of patients with HFrEF and HFpEF.

                            Product Name : JK07

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK06

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Salubris Biotherapeutics Gets EMA Approval to Begin Phase 1 Trial of JK06 in Solid Tumors

                            Details : JK06 is a first-in-class quadrivalent, biparatopic antibody drug conjugate (ADC) that selectively targets 5T4 with an MMAE payload. It is being investigated for solid tumoors.

                            Product Name : JK06

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 08, 2024

                            Lead Product(s) : JK06

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Salubris Biotherapeutics Secures $35M in Financing and Provides Pipeline Update

                            Details : JK07 is a recombinant fusion protein consisting of a fully human immunoglobulin IgG1 monoclonal antibody, which is being evaluating in the mid-stage clinical trials for patients with HFrEF and HFpEF.

                            Product Name : JK07

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Salubris Biotherapeutics

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeli...

                            Details : The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.

                            Product Name : JK07

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 28, 2023

                            Lead Product(s) : JK07

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth